Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report

BACKGROUND: As the life expectancy of cancer-bearing patients has increased, more patients with bone metastasis are receiving long-term treatment with bone-modifying agents (BMAs; e.g., zoledronate and denosumab), which are a risk factor for developing atypical femoral fracture (AFF). In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Takumi, Oh, Yoto, Sato, Shingo, Koyanagi, Hirotaka, Hirai, Takashi, Yuasa, Masato, Yoshii, Toshitaka, Nakagawa, Tsuyoshi, Miyake, Satoshi, Okawa, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334371/
https://www.ncbi.nlm.nih.gov/pubmed/32642421
http://dx.doi.org/10.1016/j.jbo.2020.100301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334371/
https://www.ncbi.nlm.nih.gov/pubmed/32642421
http://dx.doi.org/10.1016/j.jbo.2020.100301

Ejemplares similares